Solvonis Therapeutics PLC (LSE:SVNS) has taken a significant step forward in protecting its drug discovery work in the United States.
The company, which focuses on developing new treatments for addiction and mental health disorders, has had a key application accepted by the country's Patent and Trademark Office.
This protection covers a group of chemical compounds used in Solvonis’ research into the central nervous system, or CNS.
The compounds belong to a class called morpholine derivatives, initially developed by Awakn Life Sciences, which Solvonis recently acquired.
The patent application received a “first-action allowance”, meaning the patent office has approved it with no objections, and it should be formally granted after the final paperwork is completed.
Patents are crucial for pharmaceutical companies because they give exclusive rights to sell or develop a medicine for a set period, usually around 20 years from filing.
In this case, the sign-off is expected to protect Solvonis’ compounds until at least 2043 in the States, providing a competitive edge as the company advances its drug candidates through early-stage development.
Solvonis uses artificial intelligence to help discover new CNS drugs, focusing on areas such as depression and stimulant use disorders.
Chief scientific officer, Professor David Nutt, said: "This patent strengthens the foundation of our discovery platform and provides long-term protection for a chemically distinct series of CNS-active compounds already integrated into our AI-supported programme.
"The favourable examination outcome reflects the novelty and robustness of the underlying chemistry, which has now been further validated through translational screening and computational analyses."